Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
Medpage Today on MSN21h
GLP-1 Agents' Risks and Benefits Broader Than Previously ThoughtGLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...
Civic Science on MSN5d
GLP-1 Trends by CivicScience: Current Users Report Shifts in Retail Shopping and Alcohol Consumption, Plus More InsightsThis is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback